JP2008504335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504335A5 JP2008504335A5 JP2007518555A JP2007518555A JP2008504335A5 JP 2008504335 A5 JP2008504335 A5 JP 2008504335A5 JP 2007518555 A JP2007518555 A JP 2007518555A JP 2007518555 A JP2007518555 A JP 2007518555A JP 2008504335 A5 JP2008504335 A5 JP 2008504335A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- double
- building blocks
- molecule
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467804P | 2004-07-02 | 2004-07-02 | |
| US64658605P | 2005-01-26 | 2005-01-26 | |
| PCT/EP2005/007198 WO2006002971A2 (en) | 2004-07-02 | 2005-07-04 | Nucleic acids for the treatment of hmgb1-related pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504335A JP2008504335A (ja) | 2008-02-14 |
| JP2008504335A5 true JP2008504335A5 (enExample) | 2008-08-21 |
Family
ID=35106975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518555A Pending JP2008504335A (ja) | 2004-07-02 | 2005-07-04 | Ｈｍｇｂ１に関連する病変の治療のための核酸 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080305073A1 (enExample) |
| EP (1) | EP1768677B1 (enExample) |
| JP (1) | JP2008504335A (enExample) |
| AT (1) | ATE399014T1 (enExample) |
| AU (1) | AU2005259381A1 (enExample) |
| BR (1) | BRPI0512944A (enExample) |
| CA (1) | CA2572519A1 (enExample) |
| DE (1) | DE602005007746D1 (enExample) |
| DK (1) | DK1768677T3 (enExample) |
| ES (1) | ES2306195T3 (enExample) |
| IL (1) | IL179828A0 (enExample) |
| PL (1) | PL1768677T3 (enExample) |
| PT (1) | PT1768677E (enExample) |
| WO (1) | WO2006002971A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101323411B1 (ko) | 2004-08-03 | 2013-10-30 | 트랜스테크 파르마, 인크. | Ｒａｇｅ 융합 단백질 및 이의 사용 방법 |
| US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
| EP1989227A2 (en) * | 2006-02-09 | 2008-11-12 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| JP3882090B1 (ja) * | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
| KR20090087483A (ko) * | 2006-11-17 | 2009-08-17 | 클리니컬 진 네트웍스 아베 | 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법 |
| CN101589309A (zh) * | 2006-11-17 | 2009-11-25 | 临床基因网络公司 | 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法 |
| WO2009140676A2 (en) * | 2008-05-16 | 2009-11-19 | Immune Disease Institute, Inc. | Compositions and methods for inhibition of retroviruses |
| US8710021B2 (en) | 2008-06-11 | 2014-04-29 | Bionucleon S.R.L. | Inhibition of HRP-3 using modified oligonucleotides |
| BRPI0916349A2 (pt) | 2008-09-11 | 2019-09-24 | Pasteur Institut | monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1 |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| KR101431165B1 (ko) | 2008-12-22 | 2014-08-18 | 크레아빌리스 에스.에이. | 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성 |
| RU2011142230A (ru) | 2009-04-20 | 2013-05-27 | Пфайзер Инк. | Контроль гликозилирования белка и композиции и способы, касающиеся этого |
| GB0911569D0 (en) * | 2009-07-03 | 2009-08-12 | Ulive Entpr Ltd | Method for the detection of organ or tissue injury |
| JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| US8975019B2 (en) * | 2009-10-19 | 2015-03-10 | University Of Massachusetts | Deducing exon connectivity by RNA-templated DNA ligation/sequencing |
| CN103096899B (zh) | 2010-09-17 | 2015-01-28 | 独立行政法人科学技术振兴机构 | 由 hmgb 蛋白介导的免疫应答激活的抑制剂及筛选方法 |
| WO2013116590A1 (en) * | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| JP6624542B2 (ja) * | 2015-02-05 | 2019-12-25 | 国立大学法人広島大学 | ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置 |
| WO2018175301A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugate of montesanib with reduced exposure |
| WO2018175315A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates of staurosporine derivatives having reduced exposure |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| EP3621657A1 (en) | 2017-05-10 | 2020-03-18 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
| CN111304202B (zh) * | 2020-02-26 | 2023-03-28 | 西安交通大学 | 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用 |
| CN114957440A (zh) * | 2022-05-26 | 2022-08-30 | 江苏大学 | 一种重组HMGB1 A Box蛋白及其获取方法与应用 |
| US20250262230A1 (en) * | 2022-06-23 | 2025-08-21 | The Regents Of The University Of California | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease |
| CN114807150B (zh) * | 2022-06-28 | 2022-10-14 | 中国科学院基础医学与肿瘤研究所(筹) | 靶向和拮抗hmgb1分子的核酸适体 |
| JP2025525583A (ja) | 2022-07-19 | 2025-08-05 | ランパート バイオサイエンス インコーポレイテッド | 非免疫原性環状非ウイルス性ｄｎａベクター |
| CN115774004B (zh) * | 2022-08-19 | 2024-07-05 | 四川大学华西医院 | 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5442194A (en) * | 1992-10-14 | 1994-05-09 | University Research Corporation | Method for selecting nucleic acids on the basis of structure |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| NZ540067A (en) * | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
-
2005
- 2005-07-04 US US11/631,328 patent/US20080305073A1/en not_active Abandoned
- 2005-07-04 DK DK05773148T patent/DK1768677T3/da active
- 2005-07-04 JP JP2007518555A patent/JP2008504335A/ja active Pending
- 2005-07-04 WO PCT/EP2005/007198 patent/WO2006002971A2/en not_active Ceased
- 2005-07-04 CA CA002572519A patent/CA2572519A1/en not_active Abandoned
- 2005-07-04 ES ES05773148T patent/ES2306195T3/es not_active Expired - Lifetime
- 2005-07-04 AT AT05773148T patent/ATE399014T1/de not_active IP Right Cessation
- 2005-07-04 AU AU2005259381A patent/AU2005259381A1/en not_active Abandoned
- 2005-07-04 BR BRPI0512944-3A patent/BRPI0512944A/pt not_active IP Right Cessation
- 2005-07-04 PL PL05773148T patent/PL1768677T3/pl unknown
- 2005-07-04 DE DE602005007746T patent/DE602005007746D1/de not_active Revoked
- 2005-07-04 EP EP05773148A patent/EP1768677B1/en not_active Revoked
- 2005-07-04 PT PT05773148T patent/PT1768677E/pt unknown
-
2006
- 2006-12-04 IL IL179828A patent/IL179828A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504335A5 (enExample) | ||
| JP7672163B2 (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| JP5798549B2 (ja) | ヘプシジン結合核酸 | |
| JP2022036182A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| CN104053777B (zh) | 与靶蛋白质结合的核酸片段 | |
| US8835471B2 (en) | Use of angiotensin II agonists | |
| JP6944942B2 (ja) | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 | |
| JP2010533171A5 (enExample) | ||
| EA022429B1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| US20120322862A1 (en) | Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders | |
| JP2008511300A5 (enExample) | ||
| KR20220012284A (ko) | 핵산, 약학 조성물, 컨쥬게이트와 이의 제조 방법 및 용도 | |
| US20220235359A1 (en) | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | |
| JP2008518608A5 (enExample) | ||
| WO2006002971A2 (en) | Nucleic acids for the treatment of hmgb1-related pathologies | |
| CN105683377A (zh) | 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构、含有它们的组合物用于预防或治疗呼吸疾病 | |
| JP2015509705A5 (enExample) | ||
| TW202012624A (zh) | 用以調節atxn2 表達之寡核苷酸 | |
| RU2010116245A (ru) | НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a | |
| WO2023241591A1 (zh) | 调控PCSK9基因活性的siRNA分子 | |
| CN102973554B (zh) | 土木香内酯在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| TWI335219B (en) | Virus therapeutic drug | |
| JP2011505798A5 (enExample) | ||
| JP6049143B2 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| JP6993230B2 (ja) | キメラデコイ |